Baird lowered the firm’s price target on Editas Medicine (EDIT) to $4 from $8 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results where its IP update provided incremental newsflow.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EDIT:
- Editas Medicine: Hold Rating Amid Legal Uncertainty and Financial Concerns
- Buy Rating for Editas Medicine: Promising Advancements in In Vivo Gene Editing
- Editas Medicine reports Q1 EPS (92c), consensus (59c)
- Editas Medicine expects cash to fund operations into Q2 of 2027
- Editas says U.S. Court of Appeals remands CRISPR patent interference decision